ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Endocrinology, Diabetes Metabolism

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

11,000Medicare Part D Prescriptions Filled, Including Refills

Rank: 7 out of 463

$1.9M Total Retail Price of All Prescriptions

Rank: 4 out of 463

846 Patients Receiving at Least One Drug in Part D
65%Patients 65 Years and Older
55% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New York
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

3% of this provider’s 846 patients filled at least one prescription for a schedule three drug, compared to an average of 1%.

Risky Drugs to Seniors

3% of this provider’s 6,891 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

48% of this provider’s prescriptions were for brand-name drugs, compared to an average of 49%.

Prescription Price

$172 was the average price of a prescription from this provider, compared to $131 among peers.

Prescriptions per Patient

13 is the average number of prescriptions (including refills) per patient, compared to an average of 11.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New York
METFORMIN HCL 452 298 1 3
ACTOS 450 325 2 24
LEVOTHYROXINE SODIUM 414 267 3 1
LANTUS SOLOSTAR 403 218 4 4
SIMVASTATIN 328 232 5 7
NOVOFINE 306 201 10 6 111
VICTOZA 3-PAK 303 155 10 7 30
BYETTA 262 154 10 8 40
GLIMEPIRIDE 256 154 9 8
ATORVASTATIN CALCIUM 246 135 10 10
LEVEMIR FLEXPEN 241 172 11 19
JANUVIA 241 141 11 6
METFORMIN HCL ER 236 192 13 9
PRAVASTATIN SODIUM 218 141 14 43
PEN NEEDLE 216 123 15 5
PIOGLITAZONE HCL 209 134 R 10 16 68
ZETIA 205 89 17 33
AMLODIPINE BESYLATE 191 101 18 12
CRESTOR 186 82 19 13
JANUMET 178 100 20 17
ONGLYZA 163 124 21 50
NOVOLOG FLEXPEN 160 90 22 11
CARVEDILOL 140 80 23 47
LANTUS 134 99 24 16
BENAZEPRIL HCL 134 93 24 163
RAMIPRIL 123 55 26 45
ACTOPLUS MET 121 54 27 93
GLIPIZIDE ER 119 102 28 52
LOSARTAN POTASSIUM 118 86 29 20
FENOFIBRATE 107 64 30 71
GABAPENTIN 104 59 31 48
INSULIN SYRINGE 96 56 32 18
BYDUREON 95 61 33 117
OMEPRAZOLE 87 48 34 27
FUROSEMIDE 78 57 35 25
GLIPIZIDE XL 77 56 36 46
DIOVAN 77 50 36 42
ZOLPIDEM TARTRATE 76 68 38 44
METOPROLOL SUCCINATE 75 54 39 28
HYDROCODONE-ACETAMINOPHEN 72 49 S3 40 89
NOVOLOG 72 12 40 53
SYNTHROID 72 49 40 2
SPIRONOLACTONE 72 39 40 95
AMLODIPINE BESYLATE-BENAZEPRIL 71 47 44 81
VICTOZA 2-PAK 68 55 45 102
LOSARTAN-HYDROCHLOROTHIAZIDE 68 53 45 51
LISINOPRIL 67 51 47 15
HUMALOG 60 28 48 14
NATEGLINIDE 59 32 49 62
PLAVIX 58 37 50 61
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Dec. 30, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.